The U.K. was home to the world’s first coal-fired power station, opened in London in 1882. Now, it is the world’s first major economy to stop using coal to generate electricity, after closing the lone remaining coal-fired plant in the country, a station known as Ratcliffe, near the city of Nottingham.
Medical insurance company Aetna just announced that it’s going to be providing additional fertility coverage, specifically offering intrauterine insemination (IUI), to all policyholders regardless of sexual orientation or whether they’re partnered. This comes after a settlement agreement from a lawsuit earlier this year which stated that Aetna has to provide such care for LGBTQ+ people. The case, Goidel et al. v. Aetna, was filed in September 2021 and only came to a resolution in May after years of waiting and legal battles.
The new plant – located in Ramme, Denmark – is said to be capable of producing 5,000 tons of green ammonia per year, entirely from solar and wind energy. Topsoe reports that this effort will prevent 8,200 tons of carbon dioxide emissions annually. Gray ammonia production – which uses fossil fuels – is currently the norm around the globe, and accounts for about 1.2% of all carbon dioxide emissions.
The toymaker hopes gradually to bring down the amount of oil-based plastic it uses by paying up to 70% more for certified renewable resin, the raw plastic used to manufacture the bricks, in an attempt to encourage manufacturers to increase production. In the long term, Lego plans to switch entirely to renewable and recycled plastic by 2032, in a green push that has resulted in the company testing more than 600 alternative materials.
Financial close has been reached for the first two phases of the world’s largest battery storage project, the Oasis de Atacama in Chile, with 1.24GWh now financed and an eventual 4.1GWh once all five phases are completed. Grenergy expects the completed project will generate electricity equivalent for the needs of 145,000 homes and reduce CO2 emissions by over 146,000 tons.
Lung cancer is the world’s leading cause of cancer death, accounting for about 1.8 million deaths every year. Now experts are testing a new jab that instructs the body to hunt down and kill cancer cells – then prevents them from ever coming back. Known as BNT116 and made by BioNTech, the vaccine is designed to treat non-small cell lung cancer, the most common form of the disease. The phase 1 clinical trial, the first human study of BNT116, has launched across 34 research sites in seven countries: the U.K., U.S., Germany, Hungary, Poland, Spain, and Turkey.
Leading global renewable energy developer Lightsource BP has secured $NZ267 million in financing for its 168MW Kōwhai Park solar project planned to be built at the Christchurch Airport, which will be – for a time – the largest in the country. The solar farm is expected to begin construction later this year and begin operations some time in 2026. Once operational, the Kōwhai Park solar farm will generate over 275GWh per year, equivalent to the annual demand of approximately 36,000 homes.
Nepal is set to deploy Chinese-made drones to transport garbage from the slopes of Everest, marking the first time unmanned aerial vehicles (UAVs) will be used commercially in the country’s high-altitude zones. This initiative announced by China’s leading drone manufacturer, Da Jiang Innovations aims to reduce the risks faced by Sherpas and improve waste management on the world’s tallest peak.
Master Services Council, which represents 14,000 Disneyland, Disney California Adventure, and Downtown Disney employees from four unions, announced its members had voted to accept a new contract that provides a 31% pay raise over the next three years.
The “biggest wage increases ever” for Disneyland resort employees will raise hourly pay more than $6 over three years from the current $19.90 to $24 in 2024 and $26 in 2026, according to the unions.
The test, known as Shield, isn’t meant to replace colonoscopies, but is generating enthusiasm among doctors who say it has the potential to boost the dismal rate of screenings for the second-highest cause of cancer death in the United States. Shield has previously been available to doctors as a screening tool, at an out-of-pocket cost of $895. With the FDA approval, Medicare and private insurance companies are much more likely to cover the cost of the blood test, making it more widely accessible for patients.
